Glimepiride , ≥99% , 93479-97-1

Synonym(s):
trans-3-Ethyl-2,5-dihydro-4-methyl-N-[N-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide;Glimepiride;HOE-490

CAS NO.：93479-97-1

Empirical Formula: C24H34N4O5S

Molecular Weight: 490.62

MDL number: MFCD00878417

EINECS: 642-919-5

PRODUCT Properties

• Melting point: 212.2-214.5 °C
• Density: 1.29±0.1 g/cm3(Predicted)
• storage temp.: room temp
• solubility: DMSO: >10 mg/mL
• pka: 5.10±0.10(Predicted)
• form: solid
• color: white
• Merck: 14,4440
• BCS Class: 2
• CAS DataBase Reference: 93479-97-1(CAS DataBase Reference)
• EPA Substance Registry System: 1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(trans- 4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo- (93479-97-1)

Description and Uses

Glimepiride, the first of a new generation of sulfonylurea drugs, was introduced in Sweden in 1995 as a first-line therapy to lower blood glucose in patients with type II diabetes. Sulfonylureas exert their hypoglycemic function primarily by direct stimulation of insulin secretion in glucose-insensitive pancreatic β-cells and GLUT translocation in insulin-resistant fat and muscle cells. Once-daily, orally administered glimepiride in diabetes patients showed a more rapid and longer lasting glucose-lowering effect than the commonly used agent glibenclamide. Glimepiride can be used either as a monotherapy or in combination with insulin.

A sulfonylurea hypoglycemic agent. Used as an antidiabetic

Safety

• Symbol(GHS): GHS08
• Signal word: Warning
• Hazard statements: H361
• Precautionary statements: P201-P202-P280-P308+P313-P405-P501
• Hazard Codes: Xn,Xi
• Risk Statements: 21-36/38-46-62-63
• Safety Statements: 25-26-36/37-53
• WGK Germany: 3
• RTECS: UX9363950
• HS Code: 2935904000